Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Gloris Sánchez; Julio S. Castro; Soham Al Snih; Luísa Pérez Blanco; María H. Esteva; Ernesto García MacGregor; Marielena González; Ysabel Granados; Francisco Marín; Alexis Rosas; Antonio Tristano; Esther Chirinos; Luís Mundaraín; Gilberto Sanoja; Guisela Zambrano-Marín; Martín A. Rodríguez

doi:10.1007/s00296-006-0261-x

Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Gloris Sánchez, Julio S. Castro, Soham Al Snih, Luísa Pérez Blanco, María H. Esteva, Ernesto García MacGregor, Marielena González, Ysabel Granados, Francisco Marín, Alexis Rosas, Antonio Tristano, Esther Chirinos, Luís Mundaraín, Gilberto Sanoja, Guisela Zambrano-Marín, Martín A. Rodríguez

Pop Hlth & Hlth Disparities

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

Original language	English (US)
Pages (from-to)	531-536
Number of pages	6
Journal	Rheumatology International
Volume	27
Issue number	6
DOIs	https://doi.org/10.1007/s00296-006-0261-x
State	Published - Apr 2007

Keywords

Latin America
Methotrexate
Rheumatoid arthritis
Tolerability

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1007/s00296-006-0261-x

Cite this

Sánchez, G., Castro, J. S., Snih, S. A., Blanco, L. P., Esteva, M. H., MacGregor, E. G., González, M., Granados, Y., Marín, F., Rosas, A., Tristano, A., Chirinos, E., Mundaraín, L., Sanoja, G., Zambrano-Marín, G., & Rodríguez, M. A. (2007). Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. Rheumatology International, 27(6), 531-536. https://doi.org/10.1007/s00296-006-0261-x

Sánchez, G, Castro, JS, Snih, SA, Blanco, LP, Esteva, MH, MacGregor, EG, González, M, Granados, Y, Marín, F, Rosas, A, Tristano, A, Chirinos, E, Mundaraín, L, Sanoja, G, Zambrano-Marín, G & Rodríguez, MA 2007, 'Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis', Rheumatology International, vol. 27, no. 6, pp. 531-536. https://doi.org/10.1007/s00296-006-0261-x

@article{169e02c593f84cc8be43eca63871226f,

title = "Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis",

abstract = "A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.",

keywords = "Latin America, Methotrexate, Rheumatoid arthritis, Tolerability",

author = "Gloris S{\'a}nchez and Castro, {Julio S.} and Snih, {Soham Al} and Blanco, {Lu{\'i}sa P{\'e}rez} and Esteva, {Mar{\'i}a H.} and MacGregor, {Ernesto Garc{\'i}a} and Marielena Gonz{\'a}lez and Ysabel Granados and Francisco Mar{\'i}n and Alexis Rosas and Antonio Tristano and Esther Chirinos and Lu{\'i}s Mundara{\'i}n and Gilberto Sanoja and Guisela Zambrano-Mar{\'i}n and Rodr{\'i}guez, {Mart{\'i}n A.}",

note = "Funding Information: Acknowledgments We appreciate the critical review of manuscript by James S. Goodwin, M.D. and Sarah E. Toombs Smith, Ph.D., University of Texas, Galveston. We thank Mrs. Omaira P{\'e}rez, Mayra Mayora and Cruz Milano for eYcient secretarial support. Supported by Grant No G-97000808, Fondo de Ciencia, Innovaci{\'o}n y Tecnolog{\'i}a (FONACIT).",

year = "2007",

month = apr,

doi = "10.1007/s00296-006-0261-x",

language = "English (US)",

volume = "27",

pages = "531--536",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

AU - Sánchez, Gloris

AU - Castro, Julio S.

AU - Snih, Soham Al

AU - Blanco, Luísa Pérez

AU - Esteva, María H.

AU - MacGregor, Ernesto García

AU - González, Marielena

AU - Granados, Ysabel

AU - Marín, Francisco

AU - Rosas, Alexis

AU - Tristano, Antonio

AU - Chirinos, Esther

AU - Mundaraín, Luís

AU - Sanoja, Gilberto

AU - Zambrano-Marín, Guisela

AU - Rodríguez, Martín A.

N1 - Funding Information: Acknowledgments We appreciate the critical review of manuscript by James S. Goodwin, M.D. and Sarah E. Toombs Smith, Ph.D., University of Texas, Galveston. We thank Mrs. Omaira Pérez, Mayra Mayora and Cruz Milano for eYcient secretarial support. Supported by Grant No G-97000808, Fondo de Ciencia, Innovación y Tecnología (FONACIT).

PY - 2007/4

Y1 - 2007/4

N2 - A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

AB - A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

KW - Latin America

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=33947145285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947145285&partnerID=8YFLogxK

U2 - 10.1007/s00296-006-0261-x

DO - 10.1007/s00296-006-0261-x

M3 - Article

C2 - 17102944

AN - SCOPUS:33947145285

SN - 0172-8172

VL - 27

SP - 531

EP - 536

JO - Rheumatology International

JF - Rheumatology International

IS - 6

ER -

Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this